RefleXion is the first and only company to develop biology-guided radiotherapy (BgRT*), a novel treatment modality designed to use PET signals emitting from malignant lesions to guide, in real time, external-beam radiotherapy delivery. RefleXion aims to eventually treat all solid tumor types and of all cancer stages using BgRT by making external-beam radiotherapy more precise in ablating single or multiple malignant lesions. BgRT expands the use of PET tracers beyond disease diagnoses to create a new utility and new market improving radiotherapy delivery.
Initially developed for use with FDG, RefleXion is building a portfolio of PET tracers as real-time BgRT guides, including PSMA-targeted BgRT for patients with all stages of prostate cancer. RefleXion has signed collaboration agreements with both Telix Pharmaceuticals and Lantheus to develop their PSMA-targeted PET tracers for RefleXion’s X1 BgRT platform.
Visit us at booth 950 during SNMMI 2022 and for more information, visit www.reflexion.com or contact marketinginfo@reflexion.com.
Ad Statistics
Times Displayed: 345944
Times Visited: 21062 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
*The RefleXion® X1 is cleared for SBRT/SRS/IMRT. BgRT is pending regulatory review and is not commercially available.
